The role of mRNA technology in HIV vaccine development is emerging as one of the most promising avenues of research in the ongoing battle against HIV/AIDS. mRNA technology, which gained widespread attention for its role in the rapid development of vaccines against COVID-19, has revolutionized the way scientists approach vaccine design. Its flexibility, speed, and precision offer new opportunities in the fight against HIV, a virus that has proven difficult to target with traditional vaccine approaches. mRNA vaccines work by introducing a small piece of genetic material—messenger RNA—into the body. This RNA encodes the instructions for making a protein that is similar to a part of the virus, such as the spike protein in the case of COVID-19. The immune system recognizes this protein as foreign and mounts a response, which includes the production of antibodies that can neutralize the virus if encountered later. In the case of HIV, the goal is to use mRNA to prompt the immune system to recognize and respond to HIV’s specific components, particularly the viral envelope proteins, which are critical for the virus to enter human cells [1,2].
HTML PDFShare this article
Journal of AIDS & Clinical Research received 5264 citations as per Google Scholar report
